H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report) today and set a price target of $77.00.
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising long-term data from Capricor Therapeutics’ HOPE-2 trial. The trial results indicate that deramiocel, the company’s therapeutic candidate for Duchenne muscular dystrophy (DMD), has demonstrated significant efficacy in slowing disease progression and preserving muscle function over a period of more than three years.
The study’s findings, which showed a 52% reduction in disease progression compared to an external comparator group, highlight deramiocel’s potential as a durable and effective treatment option. Additionally, the therapy was well tolerated with no new safety concerns, reinforcing its favorable safety profile. With limited treatment options available for DMD, these results strengthen the case for deramiocel’s future regulatory approval and market potential.
In another report released on March 4, Piper Sandler also maintained a Buy rating on the stock with a $43.00 price target.